All research papers

Is early imaging a pitfall? Effect of [⁶⁸Ga]Ga-PSMA PET/CT timing after biopsy on SUVmax and adverse pathology prediction in low-to-intermediate risk prostate cancer.

Discovery of ¹⁷⁷Lu-PSMA-MN4 as an improved PSMA-targeted radioligand with enhanced antitumor efficacy.

Early Renal Effects After Radioactive Iodine Therapy in Differentiated Thyroid Cancer: A Prospective Observational Study.

Toward Precision Imaging in Lung NET: A Clinically Oriented Framework Integrating Dual Tracer PET and Radiomics.

PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions.

Theoretical assessment and optimization of cyclotron production routes for high-purity ^110mIn for PET applications.

Efficacy and safety of risk-adapted modified stereotactic body radiotherapy for lung tumors: a single-institution retrospective study.

Prognostic value of the Epidural Spinal Cord Compression scale, Revised Tokuhashi, and Spine Instability Neoplastic Scores in primary stereotactic body radiotherapy for spinal bone metastases.

Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial.

Endoscopic ultrasound-guided fiducial marker placement for image-guided proton beam therapy in pancreatic cancer: implications for positional accuracy and position management.

Unsupervised pelvic CBCT-to-CT translation via cross-slice attention for 3D context modeling.

Acute toxicity and patient-reported quality of life during daily online adaptive radiotherapy versus conventional IGRT for localized prostate cancer: a prospective parallel cohort study.

First dosimetric evaluation of deformable dose accumulation in human individuals.

A hybrid biokinetic-Monte Carlo framework for internal dosimetry of I-131 using a modified MIRD phantom.

Head-to-head comparison of MRI-based PI-RR scoring system and 68 Ga-PSMA-PET/CT: enhancing prostate cancer recurrence detection after radical prostatectomy.

A Digital Twin Framework for Per-Fraction Prediction of Normal Tissue Toxicity in Radiotherapy of Non-Small Cell Lung Cancer.

The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer.

Phase 1 Dose-Escalation Study of the Rapid-Clearance Radioligand [¹⁷⁷Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer: Dosimetry, Safety, and Preliminary Efficacy.

Enhancing patient safety and procedural quality in radiopharmacy: towards multidisciplinary collaboration between radiopharmacists and medical physicists.

Implementing MRI in the radiotherapy treatment position for patients with hepatobiliary malignancies: A staged feasibility evaluation.

Recombinant Human Thyrotropin Versus Thyroid Hormone Withdrawal for Radioactive Iodine Therapy in Metastatic Differentiated Thyroid Cancer: A Multicenter Retrospective Study.

Serial Multitracer PET/CT for Characterization of the Inflammation-Fibrosis Axis in Liver Injury.

Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.

Next-Generation Peptide Receptor Radionuclide Therapy: A Phase 1 Dose-Escalation and Dosimetry Study of ¹⁷⁷Lu-DOTA-EB-TATE.

Renal Function Decline After ¹⁷⁷Lu-PSMA-617 Versus Taxane-Based Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Propensity Score Analysis.

Association of <i>ATM</i> Alterations with Outcomes After ¹⁷⁷Lu-PSMA-617 Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer.

Six-year data from three magnetic resonance-guided radiotherapy systems demonstrate long-term stability of linear accelerator quality assurance.

AI-based detection of temporal changes in MR-Linac images acquired during routine prostate radiotherapy.

Hybrid geometric and evolutionary optimization framework for radiosurgery planning: isocenter selection and angle optimization for multiple brain metastases.

Risk-adapted imaging of gastric neuroendocrine neoplasms: an entity-, type-, and grade-informed framework for staging and management.

Fibroblast Activation Protein-Directed PET: Expanding FAPI Beyond Cancer.

Incremental diagnostic yield and tracer discordance of [18 F]FDOPA relative to [68Ga]Ga-DOTA-peptide PET in well-differentiated intestinal neuroendocrine tumors: a systematic review.

The "Scintigraphic Flip": A Visual Warning Sign of Impending Hematologic Toxicity.

Kidney impairment post 177Lu-PSMA radioligand therapy in metastatic prostate cancer.

Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.

CCKBR (Gastrin Receptor) as a Theranostic Target in Oncology: Biological Rationale, Diagnostic Imaging, and Next-Generation Peptide-Based Drug Development.

Case Report: Image-guided adaptive lattice radiotherapy for a 2,772-cc ulcerative triple-negative breast cancer.

MR-guided ultra-hypofractionated radiotherapy for early-stage glottic cancer: A phase I feasibility study.

LINAC-based online adaptive stereotactic ablative radiotherapy for kidney tumors: In silico analysis.

False-positive cervical lymph nodes on FAPI PET/CT after neoadjuvant chemotherapy for breast cancer: a case report.

Severe Cytopenias Following Radioligand Therapy: A Real-World Analysis.

[⁶⁸Ga]Ga-PSMA-11 PET/CT Detection of Perineural Invasion in Prostate Cancer.

MR-Linac Successfully Guided the Treatment of a Free-Moving Mesenteric Mass.

Correlation of apparent diffusion coefficient, FAP expression in IHC and [⁶⁸Ga]Ga‑FAPI‑46 uptake using integrated PET/MRI in high-grade soft tissue sarcoma: initial exploratory results.

Beyond Phenylbutyric Acid: Evans Blue and Ibuprofen as Albumin- Binding Motifs for PSMA-Targeted Radioligand Therapy of Prostate Cancer.

Feasibility of real-time near-infrared fluorescence tracer imaging in sentinel lymph node biopsy for vulvar cancer patients.

PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.

Transitioning from CA to NCA ¹⁷⁷Lu in the preparation of [¹⁷⁷Lu]Lu-DOTATATE for PRRT - observations and considerations from a retrospective review.

Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel.

Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach.

Future scenarios of radioligand therapy in pheochromocytomas and paragangliomas.

Stereotactic ablative radiotherapy for oligometastatic breast cancer: A systematic review and meta-analysis (SABRINA).

The contemporary role of stereotactic radiosurgery for surgically inoperable cerebral arteriovenous malformations.

“Imaging Triplets on Two Wheels”: 61Cu‑, 64Cu‑, and 68Ga-labeled Bicyclic Peptides Targeting Nectin‑4 Enable High-Contrast PET Imaging of Urothelial Carcinoma and Triple-Negative Breast Cancer

36.25 Gy versus 40 Gy in five fractions of curative stereotactic body radiotherapy for prostate cancer: a propensity score-matched analysis.

TP53/p53 alterations in thyroid cancer: Dedifferentiation, radioiodine refractoriness and risk stratification.

Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.

Immunogenic cell death as a mechanism of synergy between sunitinib and ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

Post-therapy imaging of adult brain tumours: patterns, pitfalls, and practical framework.

Effects of grid size and statistical uncertainty parameters on dose calculations using the Monte Carlo algorithm in the Monaco treatment planning system for liver stereotactic body radiotherapy.